In this study, we have shown that combination treatment of ovarian cancer cells with paclitaxel or carboplatin and adoptive T cell therapy in the form of ErbB-targeted CAR T cells resulted in an enhanced anti-tumor effect; greater than when either therapy was used alone. Here, EGFR is linked to ovarian cancer.